All the Active Ingredient Drugs
Alkylating Agent. Bendamustine Hydrochloride 25 mg, 100 mg. VIAL (pwdr. for concentrate. for sol. for infus.): 5x25, 100 mg. Monother. for chron. lymphoc. leuk.: 100 mg/m² bdy. surf. area bendamustine HCl on 1st and 2nd day; every 4 wks. up to 6 times.
Monother. for indolent non-Hodgkin's lymphoma. refract. to rituximab: 120 mg/m² bdy. surf. area bendamustine HCl on on 1st and 2nd day; every 3 wks. for at least 6 times.
Follic. non-Hodgkin’s lymphom.: Comb. with rituximab: The dose is 90 mg/m² bdy. surf. area Demustin I.V. on 1st and 2nd day plus 375 mg/m² rituximab on 1st day; repetit. every 4 wks.
1st-line tmt. of chron. lymphoc. leuk. (Binet stage B/C) in pts. for whom fludarabine comb. chemother. is not appropr..
Indolent non-Hodgkin's lymphoma. as monother. in pts., who have progres. during or within 6 mnths. follow. tmt. with rituximab or a rituximab contain. regimen.
Follicular non-Hodgkin’s lymphom. as 1st line tmt. in comb. with rituximab.
C/I: Hypersens. Lact. Sev. hep. impair. (serum bilirub. > 3.0 mg/dl). Jaundice. Sev. bone marrow suppres. and severe blood count alterat. (leukocyte and/or platelet values dropped to < 3,000/μl or < 75,000/μl, respectively). Major surg. less than 30 days before start of tmt. Infec., espec. involv. leukocytopenia. Yellow fever vaccin.
Alkylating Agent. Bendamustine Hydrochloride 25 mg, 100 mg. VIAL (PWDR. CONC. FOR SOL. FOR IFUS.):
1,5×100 mg, 5x25 mg.
For IV infus. over 30-60 min: Monother.
for CLL 100 mg/m² body surface area
1st day and 2nd ; every 4 weeks.
Monother. for indolent non-Hodgkin’s
lymph. refractory to rituximab 120 mg/
m² body surface area on 1st and 2nd;
every 3 weeks. Tmt. should be termin.
or delayed if leukocyte and/or platelet
values drop. to < 3,000/μl or < 75,000/
μl, respectively. Tmt. can be cont. after
leukocyte values have incr.to > 4,000/
μl and platelet values to > 100,000/μl.
1st -line tmt. of CLL (Binet stage B or C) in
pt. for whom fludarabine comb.
chemother. is not appropriate. Indolent
non-Hodgkin’s lymph. as monother. in pts.,
who have progressed during or within 6
months follow. tmt. with rituximab or a
C/I: Hypersens., lact.; Severe hep. impair.
(serum bilirubin > 3.0 mg/dl); Jaundice;
Sev. bone marrow suppres. and sev.
blood count alter. (LEU and/or PLT
values dropped to < 3,000/μl or <
75,000/μl, respectively); Major surgery <
30 days before start of tmt.; Infect.,
especially invol. leukocytopenia; Yellow